BOC International believes there is still room for further restoration in the mainland's pharmaceutical sector in the short term.
The Zhitong Finance App learned that BOC International released a research report saying that with the introduction of domestic procurement, lower cochlear implant prices are expected to increase market demand and create market share replacement space for domestic brands. The bank believes that the mainland pharmaceutical sector still has room for further restoration in the short term. It focuses on recommending innovative drug targets such as Xiansheng Pharmaceutical (02096), Hehuang Pharmaceutical (00013), Connoa-B (02162), and Kangfang Biology (09926), which are rich in short-term catalysts, have high profit growth or clear break-even time, and have high valuation flexibility to repair.
Furthermore, on September 29, the National Medical Consumables Joint Procurement Platform issued the “Notice on Launching Centralized Maintenance Work for Cochlear Implants and Peripheral Interventional Medical Consumables”, officially commencing this year's national procurement work. At present, Sichuan, Shanxi and other places have begun the process of filling in historical procurement data. On September 26, the Hebei Health Insurance Administration issued the “Notice on Continuing to Accomplish the Implementation of National Health Insurance Negotiated Drugs”, which clearly states that apart from antimicrobials, the number of types of drugs negotiated for rational use is not restricted by assessment and evaluation. Currently, Jiangsu, Shaanxi, Jiangxi and other places have also relaxed restrictions on the quantity of medicines used in national negotiations to varying degrees.
